ArticleJournal of translational medicine2026
Gut microbiota dysbiosis contributes to diabetic nephropathy via affecting renal lipid deposition and inflammatory responses.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) patients exhibit distinct patterns of gut microbiota dysbiosis. Nevertheless, the causal relationship between gut microbiota dysbiosis and DN pathogenesis remains to be established.
methodsFecal microbiota transplantation (FMT) was performed using donor samples from both DN patients and diabetic controls, with healthy donor microbiota serving as the control intervention in STZ/high-fat diet-induced DN model. Renal function was assessed by measuring biochemical indicators such as urinary protein and serum creatinine. Renal pathological changes were observed using PAS staining and Masson staining, and the composition of the intestinal microbiota was analyzed by 16 S rRNA sequencing. Furthermore, the effects of FMT-HC on renal gene expression and lipid metabolism were investigated through transcriptome sequencing, Western blotting, and Oil Red O staining.
resultsCompared with the control group, the renal function of mice with DN microbiota transplantation was significantly deteriorated, as evidenced by increased proteinuria and aggravated renal tubular interstitial fibrosis, accompanied by impaired intestinal barrier function and reduced abundance of Lactobacillus. After FMT-HC intervention, renal injury in DN mice was significantly alleviated, lipid deposition was reduced, inflammatory responses were downregulated, and beneficial bacteria such as L. johnsonii were significantly enriched in the intestine. In addition, RNA seq revealed that FMT-HC exert a protective effect on diabetic nephropathy by regulating the PPAR signaling pathway, thereby improving renal lipid metabolism disorders.
conclusionThis study demonstrates that gut microbiota dysbiosis contributes to diabetic nephropathy. The regulation of renal lipid deposition and inflammatory responses might involve the process of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.